Mesoblast Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study
12 mai 2015 05h08 HE
|
Mesoblast
NEW YORK, May 12, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC:MBLTY) today announced publication of results in the May issue of the peer-reviewed journal PLOS One showing that its...
Mesoblast Reports Positive 24 Month Results in Phase 2 Trial for Chronic Low Back Pain and Initiation of Phase 3 Program at JP Morgan Healthcare Conference
14 janv. 2015 18h13 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Jan. 14, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today presented positive 24-month results from its Phase 2 program for chronic low back...
Mesoblast's Phase 2 Trial Results In Chronic Low Back Pain Presented at North American Spine Society Annual Meeting
12 nov. 2014 18h36 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Mesoblast's Phase 2 trial results in degenerative disc disease were presented today at the North American Spine Society (NASS)...
Mesoblast Partner JCR Pharmaceuticals Files for Marketing Approval of the First Allogeneic Stem Cell Product in Japan
30 sept. 2014 20h17 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Sept. 30, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported that its Japanese partner, JCR...
Pharmaceutical Executive Joins Mesoblast As Chief Financial Officer
24 août 2014 21h16 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 24, 2014 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced the appointment of pharmaceutical executive Mr Paul Hodgkinson as...
National Institutes of Health and Mesoblast Enter Into Agreement for 120-Patient Trial In End-Stage Heart Failure
06 août 2014 20h57 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced the signing of an agreement with the United...
Mesoblast Accelerates Plans For Commercialization Manufacturing Operations In Singapore
27 mai 2014 23h10 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, May 27, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it is bringing forward plans for its...
Mesoblast Provides Update on Clinical Programs of Prochymal for Crohn's Disease and Acute Graft Versus Host Disease
28 avr. 2014 21h51 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, April 28, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided an update on its clinical programs using the...
Key Pharmaceutical Executive Joins Mesoblast
10 mars 2014 19h48 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, March 10, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that Jonathan R. Symonds, CBE, the former...
Boardroom Radio Interview with Mesoblast Chief Executive
02 févr. 2014 20h06 HE
|
Mesoblast
NEW YORK, Feb. 2, 2014 (GLOBE NEWSWIRE) -- Audio link - http://www.brrmedia.com/event/120127BRR Today at Boardroom Radio (BRR) we're once again joined by Mr Silviu Itescu, who is...